아시아 태평양 신속 진단 테스트(RDT) 시장 – 2030년까지의 산업 동향 및 예측

아시아 태평양 신속 진단 테스트(RDT) 시장 분석 및 규모

신속 진단 검사(RDT)의 발생률은 이러한 검사가 사용되거나 수행되는 빈도 또는 비율을 말합니다. 그러나 RDT의 발생률은 검사되는 특정 질병 또는 상태, 지리적 위치 및 의료 환경에 따라 크게 다를 수 있다는 점에 유의하는 것이 중요합니다. 아시아 태평양 신속 진단 검사(RDT) 시장을 주도할 것으로 예상되는 요인은 만성 질환의 발생률 증가, 노인 인구 증가, 신속 진단 검사의 기술 개발입니다. 또한 시장 참여자의 전략적 이니셔티브와 의료 지출 증가는 아시아 태평양 신속 진단 검사(RDT) 시장 성장에 대한 기회를 창출할 것으로 예상됩니다.

Data Bridge Market Research는 2022년에 13,063.46백만 달러였던 아시아 태평양 신속 진단 검사(RDT) 시장이 2030년까지 28,412.60131백만 달러에 도달할 것으로 예상하고, 2023년에서 2030년까지의 예측 기간 동안 10.2%의 CAGR을 보일 것으로 분석했습니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

아시아 태평양 신속 진단 테스트(RDT) 시장 범위 및 세분화

시장 정의

신속 진단 검사, 즉 신속 검사라고도 불리는 검사는 일반적으로 20분 이내에 빠른 결과를 제공하는 사용하기 쉬운 검사입니다. 진단 및 샘플링이 실험실로 전송되는 다른 표준 및 기존 검사와 달리 신속 진단 검사 키트에서 얻은 결과는 진료 시점에서 제공됩니다. 진료 시점은 환자가 치료되는 장소입니다. 진료 시점은 제공자의 사무실, 진료소 또는 환자의 집일 수 있습니다.

아시아 태평양 신속 진단 테스트(RDT) 시장 역학

운전자

• 감염병의 유병률

Asia-Pacific countries often face challenges related to infectious diseases, such as malaria, dengue, and various tropical illnesses. Rapid diagnostic tests are crucial in diagnosing these diseases quickly, leading to early treatment and containment, which drives the demand for RDTs in the region.

• Government Initiatives and Healthcare Investments

Many governments in the Asia-Pacific region have launched initiatives to control the spread of infectious diseases. These initiatives often include mass screening programs, which increase the demand for rapid diagnostic tests. Financial support and subsidies provided by governments further enhance the accessibility of these tests..

• Technological Advancements

Ongoing advancements in rapid diagnostic technologies, such as improved accuracy, ease of use, and the ability to test multiple diseases in a single device, are driving the adoption of RDTs. These innovations make the tests more reliable and efficient, encouraging both healthcare providers and individuals to opt for them.

• Rising Investment in Healthcare Infrastructure

Increasing investments in healthcare infrastructure, especially in developing countries within the Asia-Pacific region, lead to better healthcare facilities and services. This includes the availability of advanced diagnostic tools, including rapid tests, in hospitals, clinics, and remote healthcare centers.

Opportunities

• Expansion in Emerging Markets

Rapidly expanding healthcare infrastructure in emerging markets provides opportunities for RDT manufacturers to reach new regions, especially in rural areas with limited access to diagnostic facilities. In several Asia-Pacific countries, healthcare infrastructure is improving, leading to increased accessibility to diagnostic services. Penetration into these emerging markets with affordable and efficient RDTs can result in substantial market expansion.

• Technological Advancements

Ongoing advancements in rapid diagnostic technologies present a significant opportunity. Innovations such as smartphone-based testing apps and wearable devices for continuous monitoring are enhancing the market. Collaborations between technology companies and healthcare providers can lead to ground breaking developments.

• Home Testing from the Kits

Rising consumer preference for self-testing and home healthcare fosters the development of user-friendly RDTs for conditions like diabetes, cholesterol, and pregnancy, creating a market for home testing kits. There's a growing trend toward home-based healthcare, accelerated by the COVID-19 pandemic. RDTs that are easy to use at home for various conditions, from infectious diseases to chronic illnesses, present a vast market opportunity. Companies investing in user-friendly, reliable home test kits can capture this market.

Restraints/Challenges

• Regulatory Challenges

Stringent regulatory processes and varying standards across countries in the Asia-Pacific region pose challenges for RDT manufacturers, hindering market entry and growth. Different countries in the Asia-Pacific region have varied regulatory frameworks. Navigating these regulations, ensuring approvals, and maintaining quality standards can be a significant challenge for RDT manufacturers.

• Limited Sensitivity and Specificity

Some RDTs may have limitations in sensitivity and specificity compared to laboratory-based tests, impacting their reliability in certain diagnostic applications. Some RDTs, especially in emerging markets, might have accuracy issues. False positives or negatives can lead to misdiagnoses and inappropriate treatments, eroding trust in these tests.

• Price Sensitivity

Price sensitivity in healthcare budgets, especially in developing economies, challenges the affordability and widespread adoption of advanced RDTs, limiting market penetration. Despite advancements, some advanced RDTs can be costly. Affordability remains a challenge, especially in low-income regions where the target market might not be able to afford these tests regularly.

• Supply Chain Disruptions

Disruptions in the supply chain, as witnessed during the COVID-19 pandemic, can impact the availability and distribution of RDTs, leading to market challenges. The supply chain vulnerabilities exposed during the COVID-19 pandemic highlight potential challenges. Disruptions in the supply of critical components can hamper production and distribution, affecting the market.

This Asia-Pacific rapid diagnostic tests (RDT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific rapid diagnostic tests (RDT) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In November 2021, the Quidel Corporation had received emergency approval from the Food and Drug Administration (FDA) for the novel Sofia Q Rapid Antigen Test Device. The approval on an emergent basis was to add the Sofia Q in its latest addition of product range, along with Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA). The approval received would allow the Sofia Q rapid antigen test device to be used in telemedicine and home markets
• In August 2021, Cardinal Health partnered with Abbott and Quidel Corporation to commercialize the over-the-counter (OTC) rapid COVID-19 tests. The partnership would allow Cardinal Health to expand Cardinal Health's COVID-19 testing and surveillance offerings and be able to access Quidel's QuickVue At-Home OTC COVID-19 Test and Abbott's BinaxNOW COVID-19 Antigen Self-Test, which allow the patients to perform tests without prescription easily

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Scope

The Asia-Pacific rapid diagnostic tests (RDT) market is segmented on the basis of product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application area's difference in your target markets.

Product Type

• Kits
• Instruments
• Others

Surgery

• Professional Rapid Diagnostic Test Product
• Over-The-Counter [OTC] Rapid Diagnostic Test Product

Technology

• PCR-Based Flow-Through Assays
• Lateral Flow Immunochromatographic Assays
• Agglutination Assay
• Microfluidics
• Substrate Technology
• Others

Modality

• Laboratory Based Test
• Non-laboratory Based Test

Age group

• Adult
• Pediatric

Test type

•  Confirmation
• Serological Testing
•  Viral Sequencing

Approach

• In-Vitro Diagnostic
• Molecular Diagnostic 

Specimen

• Swab
• Blood
• Urine
• Saliva
• Sputum
• Others

Application

• Infectious Disease Testing
•  Glucose Monitoring
•  Cardiology Testing
•  Oncology Testing
•  Cardiometabolic Testing
•  Drugs-of-Abuse Testing
•  Pregnancy and Fertility Testing
•  Toxicology Testing
•  Others

End user

• Hospital and Clinic
• Diagnostic Laboratory
• Home Care Setting
• Research and Academic Institutes
• Others

Distribution Channel

• Direct Tender
• Retail Sales
• Others

Asia-Pacific Rapid Diagnostic Tests (RDT) Market Regional Analysis/Insights

The Asia-Pacific rapid diagnostic tests (RDT) market is analysed, and market size information is provided by country, product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel as referred above.

The countries covered in the Asia-Pacific rapid diagnostic tests (RDT) market report are Japan, China, India, South Korea, Australia, Singapore, Indonesia, Philippines, and the Rest of Asia-Pacific

China is expected to dominate and is fastest growing in the Asia-Pacific rapid diagnostic tests (RDT) market as it is one of the leading countries to inculcate rapid diagnostic tests (RDT) and products increases rapidly with urbanization and laboratory automation.

The country section of the Rapid Diagnostic Tests (RDT) Market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. The Rapid Diagnostic Tests (RDT) Market is analysed and market size insights and trends are provided by country, product, indication and end user as referenced above.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Asia-Pacific rapid diagnostic tests (RDT) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Asia-Pacific rapid diagnostic tests (RDT) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on Asia-Pacific rapid diagnostic tests (RDT) market. The data is available for historic period 2015-2020.

Competitive Landscape and Asia-Pacific Rapid Diagnostic Tests (RDT) Market Share Analysis

The Asia-Pacific rapid diagnostic tests (RDT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Asia-Pacific rapid diagnostic tests (RDT) market.

Some of the major players operating in the Asia-Pacific rapid diagnostic tests (RDT) market are:

• Abbott (U.S.)
• Danaher (U.S.)
• Cellex (U.S.)
• AdvaCare Pharma (China)
• Access Bio (U.S.)
• Cardinal Health (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• BD (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• bioMérieux SA (France)
• InBios International, Inc. (U.S.)
• Gnomegen LLC (U.S.)
• QIAGEN (Netherlands)
• Quidel Corporation (U.S.)
• Chembio Diagnostics Systems, Inc. (U.S.)
• Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG) (Germany)
• PerkinElmer Inc. (U.S.)
• Sekisui Diagnostics (U.S.)
• Fujirebio (A Subsidiary of H.U. Group) (Japan)
• PTS Diagnostics (U.S.)
• LamdaGen Corporation (U.S.)
• Werfen (Spain)
• Nova Biomedical (U.S.)
• Trinity Biotech (Ireland)
• Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation) (Germany)
• Luminex Corporation. A DiaSorin Company (U.S.)
• MEGAKOR DIAGNOSTK GMBH(독일)

SKU-66845